Investors might want to bet on Masimo (MASI), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

Masimo Corporation MASI delivered adjusted earnings per share (EPS) from continuing operations of $1.32 in the third quarter ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...

In a civil trial before a jury of eight, Masimo is accusing Apple of violating a patent when selling its watch over a ...

Medical tech company Masimo (NASDAQ:MASI) will be reporting results this Tuesday after market hours. Here’s what you need to know.

Masimo (Nasdaq:MASI) shares ticked up after hours today on third-quarter results that beat the consensus forecast.

Discover key insights from Masimo’s Q3 2025 earnings: strong revenue, margin expansion, and growth in AI monitoring/Philips partnership.

or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...

Two medical sector stocks that are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list are Collegium Pharmaceutical COLL and Masimo Corporation MASI. Correlated with the ...

Medical tech company Masimo (NASDAQ:MASI) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...